These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26310857)

  • 21. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
    Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
    Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
    Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].
    Zhou XJ; Zhou YH; Chen XH; Qian WB
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):834-9. PubMed ID: 23980369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
    Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
    Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
    Li XY; Li Y; Zhang L; Liu X; Feng L; Wang X
    Oncol Rep; 2017 Nov; 38(5):3114-3120. PubMed ID: 28901456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
    Ramos AM; Aller P
    Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
    Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DMFC (3,5-dimethyl-
    Xiang J; Wang Z; Liu Q; Li X; Sun J; Fung KP; Liu F
    Apoptosis; 2017 Mar; 22(3):381-392. PubMed ID: 27873035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
    Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
    Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
    Wang W; Adachi M; Zhang R; Zhou J; Zhu D
    Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.
    Visco C; Castegnaro S; Chieregato K; Bernardi M; Albiero E; Zanon C; Madeo D; Rodeghiero F
    Blood Cells Mol Dis; 2012 Jan; 48(1):68-75. PubMed ID: 22036761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
    Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
    Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
    Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
    Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
    Xiao G; Tang X; Yao C; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2011 Sep; 43(9):712-21. PubMed ID: 21785114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.